Expedite Your Drug Development

Developing molecules intended to treat interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) is a daunting challenge. It’s no easy task to predict localized drug exposure in the lungs (PBPK/PCAT™), identify applicable pharmacodynamic (PD) endpoints, and determine the efficacious levels of exposure through quantitative systems pharmacology (QSP).

Streamline this process with our integrated pulmonary software and services package, which allows you to seamlessly advance your asset from lead optimization to confidence in efficacy.

Set up a call with our experts to learn how.

Schedule a call
Utilize Targeted Software

Whether you’re focused on therapies for ILD or IPF, this package provides modeling and simulation software tailored to your needs. We’ll start by using GastroPlus® to predict localized exposure in the lungs, then leverage that localized exposure data to inform the ILDsym™ or IPFsym® platforms for efficacy predictions.

Leverage our scientists’ 40+ years of combined experience in pulmonary exposure and efficacy modeling. As they execute your project, they’ll actively train your scientists to utilize the software tools and create models that will accurately predict the exposure and efficacy of your pulmonary assets. We’ll teach you the science and show you the steps to confidently lead your own studies.

Neil Miller

Neil Miller

Vice President, PBPK Product Development
Physiologically Based Pharmacokinetics (PBPK) Solutions
Becky Graves

Becky Graves

Director, Simulation Studies
Physiologically Based Pharmacokinetics (PBPK) Solutions
Scott Q. Siler

Scott Q. Siler

Chief Science Officer
Quantitative Systems Pharmacology
Maxime Le Merdy

Maxime Le Merdy

Assoc. Dir., Res. and Collab.
Physiologically Based Pharmacokinetics (PBPK) Solutions
James Mullin

James Mullin

Sr. Principal Scientist
Physiologically Based Pharmacokinetics (PBPK) Solutions
Lisl Shoda

Lisl Shoda

Assoc. VP & Dir. of Immunol.
Quantitative Systems Pharmacology
Zackary Kenz

Zackary Kenz

Principal Scientist
Quantitative Systems Pharmacology

Hiring and retaining skilled modelers is difficult, which is why many companies develop talent from within. As part of our Pulmonary Package, your team benefits from a customized learning package using the tools in your program, implemented with support and guidance from our experts.

 

 

This will equip your existing team with the software and training to perform additional simulations outside of typical consulting service agreements, such as…

  • FIH predictions
  • Pediatric predictions
  • Disease state simulations
  • Formulation variant optimizations
  • Bioequivalence simulations
  • Drug-drug interactions
  • Food effect predictions
  • Testing the drug in virtual (diseased or healthy) populations
  • and much more!
Let us help

How Others Are Using These Tools
View all resources
Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach

Encorafenib is a kinase inhibitor indicated for the treatment of patients with BRAF mutant melanoma and BRAF mutant metastatic colorectal cancer.

Read More
ILDsym®, a Quantitative Systems Pharmacology (QSP) Platform, Successfully Simulates the Pathophysiology of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD) and Inter-patient Variability

Systemic sclerosis (SSc) is a rare connective tissue and autoimmune disease associated with inflammation of the skin and internal organs.

Read More
Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review

There are a multitude of different modelling techniques that have been used for inhaled drugs.

Read More
Proven Track Record... Regulatory Trust

14

Regulatory agencies worldwide trained on our software

1,200+

Scientists worldwide trained on our software over the past year

7

Concurrently funded collaborations with the FDA for MIDD innovation